Innoviva Inc. is targeting a third quarter relaunch of the injectable antibiotic Vibativ (telavancin) with a new pneumonia indication after working to shore up the product’s manufacturing and supply.
Theravance’s Vibativ Adds Long-Sought Pneumonia Indication
Company has secured a new third-party manufacturer for the antibiotic and says it will relaunch the drug in the third quarter. FDA approval for telavancin’s use in hospital-acquired pneumonia comes four-and-a-half years after the original NDA submission for the supplemental claim.